Should I buy Regeneron Pharmaceuticals Inc. (REGN)?

What Strong Buy means for REGN today

A Strong Buy rating is the output of the composite fair-value band ($917–$1505) compared with the live price ($715), a 9/10 moat score, and a 88/100 confidence reading on the data quality and model convergence behind the fair-value range. We do not issue Buy / Strong Buy unless valuation is in the strong half of our six-factor decision overlay AND the risk profile is non-elevated; the rating is gated, not free-form.

REGN is rated Strong Buy at $714.89 versus the reconciled fair value midpoint of $1,209.72, implying +69.22% upside/downside. Confidence is separately disclosed at 88/100. The full report explains every input: discount rate, terminal growth, deceleration curve, scenario probabilities, and where the rating could change next.

Bull, base and bear over our base horizon

Bull case (probability 20%): target $1,505.07, return +110.5%. Base case (probability 60%): target $1,209.72, return +69.2%. Bear case (probability 20%): target $917.25, return +28.3%.

Probability weights are not symmetric. Regeneron Pharmaceuticals Inc. is a mature compounder stock, so the deceleration curve, terminal P/E, and confidence in the bull tail are calibrated to that archetype. The probability-weighted expected value in the full report folds these three scenarios into a single asymmetric expected return — a more honest "should I buy?" signal than any single point estimate.

Risks to the thesis

The top kill-scenarios our latest report flags for Regeneron Pharmaceuticals Inc. are: High-Dose Eylea Fails to Defend Share; Dupixent Growth Wall; R&D Pipeline Implosion. The single biggest risk is High-Dose Eylea Fails to Defend Share: Vabysmo and early biosimilars rapidly erode Eylea's market dominance, cratering ophthalmology revenues before pipeline assets mature.

The biggest opportunity is Bull: Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505. Position management in the full report converts the rating into concrete checkpoints — quarterly reassessment triggers and the metric thresholds that should change the size of the position rather than the position itself.

Bottom line

Our Strong Buy rating with 88/100 confidence is research for educational purposes — not personalised investment advice and not a price call. Use the fair-value range and the bull/base/bear distribution to size a view; use the kill-scenarios and the earnings decision tree to define what would invalidate it.

For the full evidence — 14 sections, sensitivity grid, scorecard, and the data-provenance appendix — see the canonical report at /stocks/regn/analysis.

Frequently asked questions